Fresenius Medical Care Corporation (NYSE:FMS) will post its quarterly earnings results before the market opens on Thursday, November 2nd. Analysts expect Fresenius Medical Care Corporation to post earnings of $0.61 per share for the quarter.

Fresenius Medical Care Corporation (NYSE:FMS) last posted its quarterly earnings data on Tuesday, August 1st. The company reported $0.48 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.53 by ($0.05). The firm had revenue of $4.47 billion during the quarter, compared to analysts’ expectations of $5.20 billion. Fresenius Medical Care Corporation had a net margin of 7.06% and a return on equity of 11.57%. The company’s quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter last year, the business posted $0.96 EPS. On average, analysts expect Fresenius Medical Care Corporation to post $2.32 EPS for the current fiscal year and $2.62 EPS for the next fiscal year.

Shares of Fresenius Medical Care Corporation (FMS) opened at 48.59 on Thursday. The stock has a market cap of $29.82 billion, a price-to-earnings ratio of 20.85 and a beta of 0.48. Fresenius Medical Care Corporation has a 1-year low of $38.05 and a 1-year high of $50.22. The firm has a 50-day moving average of $48.56 and a 200 day moving average of $47.22.

COPYRIGHT VIOLATION WARNING: “Fresenius Medical Care Corporation (FMS) to Release Earnings on Thursday” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/10/26/fresenius-medical-care-corporation-fms-to-release-earnings-on-thursday.html.

Several research analysts have issued reports on FMS shares. Zacks Investment Research raised shares of Fresenius Medical Care Corporation from a “sell” rating to a “hold” rating and set a $53.00 target price for the company in a report on Monday, October 9th. Nord/LB reaffirmed a “buy” rating on shares of Fresenius Medical Care Corporation in a report on Wednesday, June 28th. Royal Bank Of Canada reaffirmed a “neutral” rating on shares of Fresenius Medical Care Corporation in a report on Tuesday, August 1st. BidaskClub cut shares of Fresenius Medical Care Corporation from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Finally, DZ Bank AG reaffirmed a “buy” rating on shares of Fresenius Medical Care Corporation in a report on Monday, August 7th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $48.50.

About Fresenius Medical Care Corporation

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Earnings History for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with MarketBeat.com's FREE daily email newsletter.